MDXG · CIK 1376339
What MiMedx Group, Inc. told the SEC could break it.
The dominant threat in MiMedx's register is reimbursement policy: effective January 1, 2026, CMS replaces the 'ASP+6%' model for skin substitutes with a flat $127.14-per-square-centimeter rate — a roughly 90% cut — that strikes directly at the economics of its core EPIFIX and EPICORD products. Its route to market is also concentrated: about 43% of 2025 sales came through its primary group purchasing organizations and integrated delivery networks, and roughly 26% through independent sales agents, so losing or renegotiating those channels would hurt. And its supply is biological — many of its allograft products depend on the availability of human-donor tissue, where any disruption could weigh on the business.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- CMS 2026 skin-substitute reimbursement overhaul (~90% cut)high
Effective January 1, 2026, CMS's '2026 Rules' replace the ASP+6% reimbursement model for skin substitutes with a flat $127.14 per square centimeter rate — cutting reimbursement by nearly 90% — directly threatening the economics of MiMedx's core EPIFIX/EPICORD products.
“Effective January 1, 2026, the 2026 Rules revolutionize skin substitute reimbursement by moving away from “Average Sales Price (ASP) +6%” model to a flat, standardized rate of $127.14 per square centimeter, cutting costs by nearly 90%.”
SEC filing →As of 2026
Customer concentration
- Channel concentration (GPOs/IDNs ~43%; independent agents ~26%)medium
About 43% of MiMedx's 2025 sales came from members of its primary Group Purchasing Organizations and Integrated Delivery Networks, and ~26% flowed through independent sales agents — concentrating revenue in a few contract channels whose loss or renegotiation could hurt sales.
“Approximately 43% of our sales in the year ended December 31, 2025 came from customers that are members of our primary GPOs or IDNs.”
SEC filing →As of 2026
Supplier concentration
- Human-donor tissue supplymedium
Many of MiMedx's allograft products depend on the availability of tissue from human donors; a disruption in donor-tissue supply could adversely affect its business.
“Many of our products depend on the availability of tissue from human donors, and any disruption in supply could adversely affect our business.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Gunze Medical (Gunze Limited)
“For example, in Japan, our distribution partner, Gunze Medical, purchases products from us and is responsible for sales to the end users for the approved indications of use and at the prevailing reimbursement rate for the product.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch